As research deepens, multiple centers at home and abroad are conducting prospective randomized controlled clinical trials to obtain more high-quality evidence-based medicine to support the application and promotion of CD19 CAR-T in the treatment of SSc and other rheumatic immune diseases (1, 54). This evidence concerns the gene CD19 and systemic sclerosis.